NovoCure Limited is an oncology company that develops and commercializes Tumor Treating Fields (TTFields) therapy, a treatment that uses electric fields to disrupt cancer cell division. The company's portfolio includes the Optune Gio device for glioblastoma, Optune Lua for non-small cell lung cancer and malignant pleural mesothelioma, and Optune Pax for locally advanced pancreatic cancer. It markets these medical devices in the United States, the European Union, the United Kingdom, Japan, Canada, and other international markets. NovoCure holds a license agreement with Zai Lab for the commercialization of its products in Greater China. The company was founded in 2000 by Professor Yoram Palti and maintains ongoing clinical trials for indications including brain metastases from non-small cell lung cancer.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage novocure.com
Sector Healthcare IR page investor.novocure.com
Tags
oncology, tumor treating fields, glioblastoma, non-small cell lung cancer, pancreatic cancer, malignant pleural mesothelioma, electric field therapy, medical devices, TTFields, Optune Gio, Optune Lua, Optune Pax, Optune Mya, Zai Lab, inovitro, inovivo
Press page —

Metrics

Valuation  
Market cap $ 1.504B
Market cap (USD) $ 1.504B
P/E -12.13
PEG —
P/BV 4.29
P/S 2.07
P/OCF —
P/FCF -61.11
Dividend yield —
Turnover / mcap —
Returns  
ROE -38.9%
ROI -25.4%
ROIC -21.5%
Profit margin -20.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 57.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 31
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 655.353M 605.22M 509.338M 537.84M 535.031M 494.366M 351.318M 248.069M 177.026M 82.888M 33.087M 15.49M
Net profit -136.227M -168.627M -207.043M -92.534M -58.351M 19.808M -7.23M -63.559M -61.662M -131.845M -111.581M -80.682M
Free cash flow -75.679M -69.224M -100.429M 9.43M 58.586M 84.18M 16.135M -4.781M -35.593M -113.266M -104.551M -75.093M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 12.93 29.8 14.93 73.35 75.08 173.04 84.27 33.48 20.2 7.85 22.36 —
Price performance 12m -0.57 1 -0.8 -0.02 -0.57 1.05 1.52 0.66 1.57 -0.65 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 6.34M 29.6M 36.5M 58.9M 96.7M 93.6M 86.3M 61.2M 74.2M 89.4M
↳ YoY growth +366.4% +23.5% +61.2% +64.3% -3.2% -7.8% -29.0% +21.2% +20.5%
↳ 5y CAGR +71.3% +23.9% +10.9% +4.7% -1.5%
Borrowings, current (USD) 70,000 32,000 31,000 — — — — — — 0.00
Borrowings, non-current (USD) 96.2M 97.3M 149M 149M 430M 562M 566M 569M 97.3M 195M
Lease liabilities (USD) — — 0.00 18.8M 20.8M 19.7M 24.6M 35.6M 27.9M 53.3M
Cash and deposits (USD) 99.8M 78.6M 141M 177M 235M 209M 115M 241M 164M 93.5M
Right-of-use assets (USD) — — 0.00 17.6M 19M 18.3M 23.6M 34.8M 27.1M 47.3M
Net debt (borrowings + leases - cash) (USD) -3.48M 18.8M 8.68M -9.12M 216M 373M 475M 364M -38.6M 155M
Cash flow detail
Operating cash flow (USD) -108M -33.1M -1.87M 26.6M 99.1M 82.8M 30.8M -73.3M -26.4M -49M
Purchases of property, plant and equipment (USD) -5.67M -2.46M -2.92M -10.5M -15M -24.2M -21.4M -27.1M -42.9M -26.6M
Change in receivables (cash effect) (USD) -6.34M -23.2M -4.15M -36.5M -30.4M 5.27M 2.55M — — —
Change in inventories (cash effect) (USD) -12M 3.52M -529,000 -1.16M -2.94M 2.48M -4.34M -8.92M 2.57M -5.67M
Change in payables (cash effect) (USD) — 13.3M 13.7M 16.9M 25.5M 27.8M 14.3M 14.9M 19.1M 19M
Dividends paid (cash effect) (USD) 0.00 0.00 — — — — — — — —
Interest paid (cash effect) (USD) -6.6M -10.2M -13.3M -13.7M -8.69M -101,000 -41,000 -6,000 -7.71M -13.4M
Income taxes paid (cash effect) (USD) -9.45M -10.3M -20.4M -11.2M 3.26M -3.11M -5.48M -13.7M -23.5M -30.7M
Share-based compensation (USD) 22.1M 27.1M 39.8M 52.4M 75.7M 94.9M 107M 116M 160M 105M
Operating cash flow before change in receivables (USD) -101M -9.91M 2.29M 63.1M 130M 77.5M 28.2M — — —
Free cash flow (OCF - PPE - intangibles) (USD) -113M -35.6M -4.78M 16.1M 84.2M 58.6M 9.43M -100M -69.2M -75.7M
Income detail
Research and development expense (USD) 41.5M 38.1M 50.6M 79M 132M 201M 206M 223M 210M 225M
↳ 5y CAGR +7.8% +14.4% +24.7% +37.2% +40.2% +34.6% +21.6% +11.2%
Total comprehensive income (USD) -132M -61.1M -63.6M -8.6M 18.7M -57.7M -91.8M -210M -169M -134M
Comprehensive income to owners (USD) -132M -61.1M -63.6M -8.6M 18.7M -57.7M -91.8M -210M -169M -134M
Reported Feb 23, 2017 Feb 27, 2020 Oct 31, 2019 Feb 27, 2020 Feb 25, 2021 Feb 24, 2022 Feb 23, 2023 Feb 22, 2024 Feb 27, 2025 Oct 29, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

BAAR, Switzerland—November 9, 2026-- Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation.

The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune Mya prevented approval of the PMA application. The FDA did not raise concerns related to the safety profile of Optune Mya. Novocure is evaluating the feedback and plans to meet with the FDA to determine if there are any options that would support approval of the PMA application that would not require additional clinical studies. There can be no assurance that these discussions or any future submissions regarding this PMA application will lead to an approval.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields.

October 29, 2026

PDF Version

Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide

Strong performance drove increased net revenue guidance for full-year 2026 to $736 million - $743 million and adjusted EBITDA guidance to $24 million - $34 million

Optune Pax® approved by Japan's Ministry of Health, Labour and Welfare for the treatment of locally advanced pancreatic cancer

BAAR, Switzerland--(BUSINESS WIRE)--Oct. 29, 2026-- Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

“Novocure’s strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies,” said Frank Leonard, CEO, Novocure. “We achieved record-high quarterly net revenue and are well-positioned to achieve the commercial, clinical and financial goals we set out in January. Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability.”

Financial updates for the quarter ended September 30, 2026:

  • Total net revenues for the quarter were $193.4 million, an increase of 16% compared to the same period in 2025. This increase was primarily driven by 19% global active patient growth.

  • The U.S., Germany, France and Japan contributed $111.9 million, $24.9 million, $18.7 million and $14.5 million, respectively, with other active markets contributing $18.8 million.

  • $4.4 million in net revenue recognized from one-time benefits in the U.S. and Germany related to increases in claims approval rates.

  • Net revenue from Optune Lua® and Optune Pax® in the quarter was $11.9 million.

  • Recognized revenue from Optune Lua in the quarter was $8.2 million. The U.S., Germany and Japan contributed $2.3 million, $1.8 million and $4.1 million, respectively.

  • Recognized revenue from Optune Pax in the quarter was $3.7 million, substantially all from sales in the U.S.

  • Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $4.5 million.

  • Gross margin for the quarter was 77% compared to 73% in the prior year. This improvement was primarily driven by higher net revenue primarily attributable to higher active patient volumes in conjunction with lower cost of revenues per active patient, driven primarily by improved array utilization and manufacturing efficiencies.

  • Research, development and clinical study expenses for the quarter were $58.1 million, an increase of 8% from the same period in 2025. This increase was primarily driven by an increase in clinical trial expenses mostly attributable to KEYNOTE D58.

  • Sales and marketing expenses for the quarter were $53.3 million, a decrease of 9% compared to the same period in 2025. This decrease was primarily driven by lower share-based compensation expenses and lower marketing expenses.

  • General and administrative expenses for the quarter were $43.6 million, a decrease of 5% compared to the same period in 2025. This decrease was primarily driven by lower share-based compensation expenses.

  • Net loss for the quarter was $10.4 million with loss per share of $0.09.

  • Adjusted EBITDA* for the quarter was $15.7 million.

  • Cash, cash equivalents and short-term investments were $463.5 million as of September 30, 2026.

Operational updates for the quarter ended September 30, 2026:

  • As of September 30, 2026, there were 5,260 total active patients on TTFields therapy globally.

  • Optune Gio

  • As of September 30, 2026, there were 4,729 active patients on Optune Gio, an increase of 11% from the same period in 2025.

  • The U.S., Germany, France and Japan contributed 2,324; 656; 493 and 592 active patients, respectively, with 664 active patients contributed by other active markets.

  • Optune Lua

  • As of September 30, 2026, there were 255 active patients on Optune Lua, an increase of 83% from the same period in 2025.

  • The U.S., Germany, France and Japan contributed 97; 42; 1 and 110 active patients, respectively, with 5 active patients contributed by other active markets.

  • Optune Pax

  • 238 prescriptions for Optune Pax were received in the quarter. The U.S. and Germany contributed 209 and 29 prescriptions, respectively.

  • As of September 30, 2026, there were 276 active patients on Optune Pax. The U.S. and Germany contributed 266 and 10 active patients, respectively.

Quarterly updates and recent achievements:

  • October 2026

  • Optune Pax received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.

  • Novocure entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of TTFields therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer.

2026 Financial Guidance:

Novocure’s updated guidance for the full year 2026, as of October 29, 2026, is summarized below:

  • Total net revenue: $736 million - $743 million (previous: $710 million - $725 million)

  • Adjusted EBITDA*: $24 million - $34 million (previous: $0 million - $15 million)

This guidance assumes full-year mid-to-high single digit net revenue growth from Optune Gio, net revenue contribution from Optune Lua and Optune Pax, collectively, between $30 million and $34 million, foreign exchange rates as of September 30, 2026, and quarterly gross margin in the mid-to-high 70s percent.

Anticipated clinical and regulatory milestones:

  • Decision by the U.S. FDA on the premarket approval application for use of TTFields therapy for the treatment of brain metastases from non-small cell lung cancer (Q4 2026).

  • Complete enrollment in Phase 3 KEYNOTE D58 clinical trial in newly diagnosed glioblastoma (Q4 2026).

Conference call details

Novocure will host a conference call and webcast to discuss third quarter 2026 financial results at 8:00 a.m. EDT today, Thursday, October 29, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, investor.novocure.com, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.

Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X.

*Non-GAAP Financial Measurements

We measure our performance based upon a non-U.S. GAAP measurement of earnings before interest, taxes, depreciation, amortization and shared-based compensation ("Adjusted EBITDA"). We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare the results of our operations from period to period by removing the impact of earnings attributable to our capital structure, tax rate and material non-cash items, specifically share-based compensation.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 26, 2026, and subsequent flings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

| NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS |

| U.S. dollars in thousands (except share and per share data) |

| | Three months ended September 30, | | Nine months ended September 30, | | Year ended December 31, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | | | | 2025 | |

| | Unaudited | | Unaudited | | Audited |

| Net revenues | $ | 193,399 | | | $ | 167,204 | | | $ | 551,038 | | | $ | 481,003 | | | $ | 655,353 | |

| Cost of revenues | | 44,529 | | | | 44,729 | | | | 124,564 | | | | 124,722 | | | | 166,879 | |

| Gross profit | | 148,870 | | | | 122,475 | | | | 426,474 | | | | 356,281 | | | | 488,474 | |

| | | | | | | | | | |

| Operating costs and expenses: | | | | | | | | | |

| Research, development and clinical studies | | 58,099 | | | | 54,029 | | | | 167,883 | | | | 163,639 | | | | 224,544 | |

| Sales and marketing | | 53,297 | | | | 58,546 | | | | 173,338 | | | | 171,404 | | | | 240,064 | |

| General and administrative | | 43,645 | | | | 45,921 | | | | 169,406 | | | | 134,645 | | | | 177,666 | |

| Total operating costs and expenses | | 155,041 | | | | 158,496 | | | | 510,627 | | | | 469,688 | | | | 642,274 | |

| | | | | | | | | | |

| Operating income (loss) | | (6,171 | ) | | | (36,021 | ) | | | (84,153 | ) | | | (113,407 | ) | | | (153,800 | ) |

| Financial income (expenses), net | | (1,709 | ) | | | 5,999 | | | | (5,437 | ) | | | 18,111 | | | | 17,550 | |

| | | | | | | | | | |

| Income (loss) before income tax | | (7,880 | ) | | | (30,022 | ) | | | (89,590 | ) | | | (95,296 | ) | | | (136,250 | ) |

| Income tax | | 2,555 | | | | 7,248 | | | | 7,641 | | | | 16,432 | | | | (23 | ) |

| Net income (loss) | $ | (10,435 | ) | | $ | (37,270 | ) | | $ | (97,231 | ) | | $ | (111,728 | ) | | $ | (136,227 | ) |

| | | | | | | | | | |

| Basic and diluted net income (loss) per ordinary share | $ | (0.09 | ) | | $ | (0.33 | ) | | $ | (0.84 | ) | | $ | (1.00 | ) | | $ | (1.22 | ) |

| Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share | | 116,785,198 | | | | 111,908,252 | | | | 115,685,559 | | | | 111,259,532 | | | | 111,471,991 | |

Consolidated Balance SheetsUSD in thousands (except share data)

| NOVOCURE LIMITED AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS |

| U.S. dollars in thousands (except share data) |

| | September 30, 2026 | | December 31, 2025 |

| | Unaudited | | Audited |

| ASSETS | | | |

| CURRENT ASSETS: | | | |

| Cash and cash equivalents | $ | 96,734 | | | $ | 93,548 | |

| Short-term investments | | 366,745 | | | | 354,126 | |

| Restricted cash | | 10,106 | | | | 9,842 | |

| Trade receivables, net | | 108,260 | | | | 89,435 | |

| Receivables and prepaid expenses | | 51,069 | | | | 58,669 | |

| Inventories | | 40,605 | | | | 41,111 | |

| Total current assets | | 673,519 | | | | 646,731 | |

| LONG-TERM ASSETS: | | | |

| Property and equipment, net | | 72,667 | | | | 77,606 | |

| Field equipment, net | | 28,362 | | | | 22,066 | |

| Right-of-use assets | | 43,063 | | | | 47,327 | |

| Other long-term assets | | 11,097 | | | | 10,596 | |

| Total long-term assets | | 155,189 | | | | 157,595 | |

| TOTAL ASSETS | $ | 828,708 | | | $ | 804,326 | |

| | | | |

| |

| LIABILITIES AND SHAREHOLDERS' EQUITY | | | |

| CURRENT LIABILITIES: | | | |

| Current maturity of senior secured credit facility | $ | 25,000 | | | $ | — | |

| Trade payables | | 145,918 | | | | 122,231 | |

| Other payables, lease liabilities and accrued expenses | | 99,741 | | | | 100,997 | |

| Total current liabilities | | 270,659 | | | | 223,228 | |

| LONG-TERM LIABILITIES: | | | |

| Senior secured credit facility, net | | 171,337 | | | | 195,047 | |

| Long-term leases | | 35,217 | | | | 41,647 | |

| Employee benefit liabilities | | 882 | | | | 3,938 | |

| Total long-term liabilities | | 207,436 | | | | 240,632 | |

| | | | |

| TOTAL LIABILITIES | | 478,095 | | | | 463,860 | |

| COMMITMENTS AND CONTINGENCIES | | | |

| | | | |

| SHAREHOLDERS' EQUITY: | | | |

| Share capital - | | | |

| Ordinary shares no par value, Unlimited shares authorized; issued and outstanding: 116,914,114 shares and 112,492,667 shares at September 30, 2026 (unaudited) and December 31, 2025, respectively | | — | | | | — | |

| Additional paid-in capital | | 1,739,793 | | | | 1,634,264 | |

| Accumulated other comprehensive income (loss) | | (1,592 | ) | | | (3,441 | ) |

| Retained earnings (accumulated deficit) | | (1,387,588 | ) | | | (1,290,357 | ) |

| TOTAL SHAREHOLDERS' EQUITY | | 350,613 | | | | 340,466 | |

| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 828,708 | | | $ | 804,326 | |

Non-U.S. GAAP Financial Measures ReconciliationUSD in thousands

| | Three months ended September 30, | | Nine months ended September 30, |

| | | 2026 | | | | 2025 | | | % Change | | | 2026 | | | | 2025 | | | % Change |

| Net income (loss) | $ | (10,435 | ) | | $ | (37,270 | ) | | (72 | )% | | $ | (97,231 | ) | | $ | (111,728 | ) | | (13 | )% |

| Add: Income tax | | 2,555 | | | | 7,248 | | | (65 | )% | | | 7,641 | | | | 16,432 | | | (53 | )% |

| Add: Financial expenses (income), net | | 1,709 | | | | (5,999 | ) | | (128 | )% | | | 5,437 | | | | (18,111 | ) | | (130 | )% |

| Add: Depreciation and amortization | | 4,416 | | | | 3,663 | | | 21 | % | | | 12,847 | | | | 10,432 | | | 23 | % |

| EBITDA | $ | (1,755 | ) | | $ | (32,358 | ) | | (95 | )% | | $ | (71,306 | ) | | $ | (102,975 | ) | | (31 | )% |

| Add: Share-based compensation | | 17,483 | | | | 29,321 | | | (40 | )% | | | 97,504 | | | | 85,016 | | | 15 | % |

| Adjusted EBITDA | $ | 15,728 | | | $ | (3,037 | ) | | (618 | )% | | $ | 26,198 | | | $ | (17,959 | ) | | (246 | )% |

Active Patients at Period End

| | September 30, |

| | 2026 | | 2025 |

| | Optune Gio | | Optune Lua | | Optune Pax | | Total | | Optune Gio | | Optune Lua | | Optune Pax | | Total |

| Active patients at period end | | | | | | | | | | | | | | | |

| United States | 2,324 | | 97 | | 266 | | 2,687 | | 2,176 | | 104 | | — | | 2,280 |

| International markets: | | | | | | | | | | | | | | | |

| Germany | 656 | | 42 | | 10 | | 708 | | 595 | | 31 | | — | | 626 |

| France | 493 | | 1 | | — | | 494 | | 499 | | — | | — | | 499 |

| Japan | 592 | | 110 | | — | | 702 | | 474 | | — | | — | | 474 |

| Other international | 664 | | 5 | | — | | 669 | | 533 | | 4 | | — | | 537 |

| International markets - Total | 2,405 | | 158 | | 10 | | 2,573 | | 2,101 | | 35 | | — | | 2,136 |

| | | | | | | | | | | | | | | | |

| | 4,729 | | 255 | | 276 | | 5,260 | | 4,277 | | 139 | | — | | 4,416 |

Indication and Important Safety Information for Optune Gio®

What is Optune Gio ® approved to treat?

Optune Gio is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune Gio is used together with a chemotherapy called temozolomide (TMZ) if:

  • Your cancer is confirmed by your healthcare professional AND

  • You have had surgery to remove as much of the tumor as possible

Recurrent GBM

If your tumor has come back, Optune Gio can be used alone as an alternative to standard medical therapy if:

  • You have tried surgery and radiation and they did not work or are no longer working AND

  • You have tried chemotherapy and your GBM has been confirmed by your healthcare professional

Who should not use Optune Gio?

Optune Gio is not for everyone. Talk to your doctor if you have:

  • An implanted medical device (programmable shunt), skull defect (missing bone with no replacement), or bullet fragment. Optune Gio has not been tested in people with implanted electronic devices, which may cause the devices not to work properly, and Optune Gio has not been tested in people with skull defects or bullet fragments, which may cause Optune Gio not to work properly

  • A known sensitivity to conductive hydrogels (the gel on the arrays placed on the scalp like the ones used on EKGs). When Optune Gio comes into contact with the skin, it may cause more redness and itching or may rarely cause a life-threatening allergic reaction

Do not use Optune Gio if you are pregnant or are planning to become pregnant. It is not known if Optune Gio is safe or effective during pregnancy.

What should I know before using Optune Gio?

Optune Gio should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Gio.

  • Do not use any parts that did not come with the Optune Gio Treatment Kit sent to you by Novocure or given to you by your doctor

  • Do not get the device or transducer arrays wet

  • If you have an underlying serious skin condition on the scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune Gio treatment

What are the possible side effects of Optune Gio?

Most common side effects of Optune Gio when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression. The most common side effects when using Optune Gio alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers. Talk to your doctor if you have any of these side effects or questions.

Please visit OptuneGio.com for Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

Indication and Important Safety Information for Optune Lua®

What is Optune Lua ® approved to treat?

Optune Lua is a wearable, portable, FDA-approved device used together with PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel. It is indicated for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.

Who should not use Optune Lua?

Optune Lua for mNSCLC is not for everyone. Talk to your doctor if you have:

  • An electrical implant. Use of Optune Lua together with electrical implants has not been tested and may cause the implanted device not to work properly

  • A known sensitivity to gels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergies such as a fall in blood pressure and difficulty breathing

  • Do not use Optune Lua if you are pregnant or are planning to become pregnant. It is not known if Optune Lua is safe or effective during pregnancy.

What should I know before using Optune Lua?

Optune Lua should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Lua.

  • Do not use any parts that did not come with Optune Lua Treatment Kit sent to you by Novocure or given to you by your doctor

  • Do not get the device or transducer arrays wet

  • Please be aware that Optune Lua has a cord that plugs into an electrical socket. Be careful of tripping when it’s connected

  • If you have an underlying serious skin condition where the transducer arrays are placed, discuss with your doctor whether this may prevent or temporarily interfere with Optune Lua treatment.

What are the possible side effects of Optune Lua?

The most common side effects of Optune Lua when used together with certain immunotherapy and chemotherapy drugs were dermatitis, pain in the muscles, bones, or joints, fatigue, anemia, alopecia (hair loss), dyspnea, nausea, cough, diarrhea, anorexia, pruritus (itching), leukopenia, pneumonia, respiratory tract infection, localized edema (swelling), rash, pain, constipation, skin ulcers, hypokalemia (low potassium levels), hypoalbuminemia (low albumin levels), hyponatremia (low sodium levels), and dysphagia (difficulty swallowing).

Other potential adverse effects associated with the use of Optune Lua include treatment related skin irritation, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown/skin ulcer. Talk to your doctor if you have any of these side effects or questions.

Please visit OptuneLua.com for Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

Indication and Important Safety Information for Optune Pax®

What is Optune Pax® approved to treat?

Optune Pax is an FDA-approved wearable therapeutic device, used together with gemcitabine and nab-paclitaxel (a chemotherapy combination). It is indicated for the treatment of adult patients with locally advanced pancreatic cancer.

Who should not use Optune Pax?

Optune Pax for locally advanced pancreatic cancer is not for everyone. Talk to your doctor if you have:

  • An electrical implant. Use of Optune Pax together with electrical implants has not been tested and may cause the implanted device not to work properly.

  • A known sensitivity to gels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with Optune Pax may commonly cause increased redness and itching. In rare cases, it may lead to severe allergic reactions that can cause a drop in blood pressure and difficulty breathing

  • Do not use Optune Pax if you are pregnant or are planning to become pregnant. If you are a woman who is able to get pregnant, you must use birth control when using the device. It is not known if Optune Pax is safe or effective during pregnancy.

What should I know before using Optune Pax?

Optune Pax should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Pax.

  • Do not use any parts that did not come with the Optune Pax Treatment Kit sent to you by Novocure or given to you by your doctor

  • Do not get the device or transducer arrays wet

  • Please be aware that Optune Pax has a cord that plugs into an electrical socket. Be careful of tripping when it's connected

  • If you have an underlying skin condition where the transducer arrays are placed, discuss with your doctor whether this may prevent or temporarily interfere with Optune Pax treatment

What are the possible side effects of Optune Pax?

The most common side effects of Optune Pax used together with chemotherapy drugs were low neutrophils, low red blood cell count, low platelet count, low white blood cell count, diarrhea, nausea, vomiting, abdominal pain, constipation, fatigue, swelling, fever, pain, COVID-19, infection, respiratory tract infection, urinary tract infection, pneumonia, liver enzyme increased, weight loss, low potassium level, low albumin level, high blood sugar, muscle pain, neuropathy peripheral (damage to the nerves outside the brain and spinal cord), taste disorder, dizziness, difficulty sleeping, shortness of breath, hair loss, skin-related disorders, and low blood pressure.

Device-related skin adverse effects associated with the use of Optune Pax include skin inflammation, rash, itching, skin redness, skin irritation, skin infection, heavy sweating, and open sores. Other device-related adverse effects associated with the use of Optune Pax include overheating of the array, leading to pain and/or local skin burns, allergic reaction to the adhesive or gel from the transducer arrays, and local warmth and tingling sensation beneath the arrays. Talk to your doctor if you have any of these side effects or have any questions.

Please visit OptunePax.com for Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029363518/en/

Investors: Adam Daney [email protected]

Media: Catherine Falcetti [email protected]

Source: Novocure

Search Investors

October 28, 2026

PDF Version

BAAR, Switzerland--(BUSINESS WIRE)--Oct. 28, 2026--

Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer.

“Meaningful progress has been made in the treatment of pancreatic cancer and we are proud that Tumor Treating Fields therapy is one of the new options available to patients. However, advanced pancreatic cancer remains one of the most difficult cancers to treat,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “Based on results we observed in pre-clinical models, we believe that the physical modality of Tumor Treating Fields therapy used together with a KRAS inhibitor has the potential to be an effective new treatment approach in pancreatic cancer. Through our collaboration with Verastem Oncology, we will evaluate the use of Tumor Treating Fields therapy, chemotherapy and VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, as a novel treatment approach for patients with this challenging cancer.”

“We are excited to build on Novocure’s work advancing Tumor Treating Fields therapy for pancreatic cancer by evaluating it in combination with chemotherapy and VS-7375, our potentially best-in-class oral, potent and selective KRAS G12D (ON/OFF) inhibitor, in locally advanced pancreatic cancer,” said Michael Kauffman, MD, PhD, president of development at Verastem Oncology. “This collaboration will allow us to explore whether these treatment approaches, when used together, can drive deeper and more durable responses for these patients living with pancreatic cancer.”

Novocure plans to initiate a clinical trial to evaluate the safety and tolerability of TTFields therapy concomitant with gemcitabine, nab-paclitaxel, and VS-7375 in approximately 25 patients with locally advanced pancreatic cancer. Preliminary efficacy is planned to be evaluated as exploratory endpoints. Under the terms of the agreement, Novocure will manage and fund the clinical trial operations and Verastem will supply VS-7375 for the planned clinical trial. The trial is expected to begin enrolling patients in 2027.

About Tumor Treating Fields

Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multi-mechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and it demonstrated enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors.

To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit novocure.com/ttfields.

About Pancreatic Cancer

According to the World Health Organization (WHO), pancreatic cancer is one of the most lethal cancers. It is the third most frequent cause of death from cancer in the U.S. and is the fifth most frequent cause of death from cancer in Europe.1 While overall cancer incidence and death rates are remaining stable or declining, the incidence and death rates for pancreatic cancer are increasing.2 Pancreatic cancer has a five-year relative survival rate of just 13%.3

Physicians use different combinations of surgery, radiation, and pharmacological therapies to treat pancreatic cancer, depending on the stage of the disease. Unfortunately, most locally advanced pancreatic cancer cases are diagnosed when the cancer is no longer operable, leaving few treatment options. The standard of care for locally advanced pancreatic cancer is chemotherapy with or without radiation, and surgery if it is possible.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.

Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X.

Novocure Forward-Looking Statement

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 26, 2026, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Indication and Important Safety Information for Optune Pax®

What is Optune Pax® approved to treat?

Optune Pax is an FDA-approved wearable therapeutic device, used together with gemcitabine and nab-paclitaxel (a chemotherapy combination). It is indicated for the treatment of adult patients with locally advanced pancreatic cancer.

Who should not use Optune Pax?

Optune Pax for locally advanced pancreatic cancer is not for everyone. Talk to your doctor if you have:

An electrical implant. Use of Optune Pax together with electrical implants has not been tested and may cause the implanted device not to work properly.

A known sensitivity to gels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with Optune Pax may commonly cause increased redness and itching. In rare cases, it may lead to severe allergic reactions that can cause a drop in blood pressure and difficulty breathing

Do not use Optune Pax if you are pregnant or are planning to become pregnant. If you are a woman who is able to get pregnant, you must use birth control when using the device. It is not known if Optune Pax is safe or effective during pregnancy.

What should I know before using Optune Pax?

Optune Pax should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Pax.

Do not use any parts that did not come with the Optune Pax Treatment Kit sent to you by Novocure or given to you by your doctor

Do not get the device or transducer arrays wet

Please be aware that Optune Pax has a cord that plugs into an electrical socket. Be careful of tripping when it's connected

If you have an underlying skin condition where the transducer arrays are placed, discuss with your doctor whether this may prevent or temporarily interfere with Optune Pax treatment

What are the possible side effects of Optune Pax?

The most common side effects of Optune Pax used together with chemotherapy drugs were low neutrophils, low red blood cell count, low platelet count, low white blood cell count, diarrhea, nausea, vomiting, abdominal pain, constipation, fatigue, swelling, fever, pain, COVID-19, infection, respiratory tract infection, urinary tract infection, pneumonia, liver enzyme increased, weight loss, low potassium level, low albumin level, high blood sugar, muscle pain, neuropathy peripheral (damage to the nerves outside the brain and spinal cord), taste disorder, dizziness, difficulty sleeping, shortness of breath, hair loss, skin-related disorders, and low blood pressure.

Device-related skin adverse effects associated with the use of Optune Pax include skin inflammation, rash, itching, skin redness, skin irritation, skin infection, heavy sweating, and open sores. Other device-related adverse effects associated with the use of Optune Pax include overheating of the array, leading to pain and/or local skin burns, allergic reaction to the adhesive or gel from the transducer arrays, and local warmth and tingling sensation beneath the arrays. Talk to your doctor if you have any of these side effects or have any questions.

Please visit OptunePax.com for Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

CAUTION—The use of TTFields therapy together with KRAS inhibitors for pancreatic cancer is investigational.


1 International Agency for Research on Cancer. 2024. Cancer Today (GLOBOCAN 2022). https://gco.iarc.who.int/today/en/dataviz/tables?mode=cancer&group_populations=1&populations=908&multiple_populations=1&types=1 Accessed on June 16, 2026. 2 American Cancer Society. Cancer Facts & Figures 2025. 1930;(500825). https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf Accessed January 16, 2026. 3 American Cancer Society. Cancer Facts & Figures 2026. Atlanta: American Cancer Society; 2026

View source version on businesswire.com: https://www.businesswire.com/news/home/20261028077167/en/

Investors: Adam Daney [email protected]

Media: Catherine Falcetti [email protected]

Source: Novocure

Search Investors

Prompts

NovoCure Limited (ticker NVCR), listed in United States.

ETFs Holding NovoCure Limited

ETF Weight in ETF Shares Market value As of
BRNY 0.47% 235,002 $ 2.62M Nov 18, 2026
BRES 0.35% 193,342 $ 2.15M Nov 18, 2026
TMED 0.31% 4,764 $ 72.175K Jun 30, 2026
FSML 0.19% 15,812 $ 239.552K Jun 30, 2026
DTAN 0.19% 3,624 $ 40.371K Nov 17, 2026
DFAS 0.02% 493,688 $ 5.786M Nov 12, 2026
DFAC 0.00% 109,477 $ 1.283M Nov 12, 2026
DFSU 0.00% 2,137 $ 25.046K Nov 12, 2026
DFUS 0.00% 18,783 $ 220.137K Nov 12, 2026
DFAU 0.00% 7,332 $ 85.931K Nov 12, 2026
DCOR 0.00% 20,968 $ 245.745K Nov 12, 2026